Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-04958242
Drug: Placebo

First Posted Date: 2014-08-29

Last Posted Date: 2020-01-07

Lead Sponsor: Biogen

Target Recruit Count: 12

Registration Number: NCT02228395

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Other: Placebo
Drug: BIIB061

First Posted Date: 2014-08-29

Last Posted Date: 2016-06-15

Lead Sponsor: Biogen

Target Recruit Count: 56

Registration Number: NCT02228707

Locations: 🇺🇸
Research Site, Madison, Wisconsin, United States

Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Placebo
Drug: fampridine

First Posted Date: 2014-08-19

Last Posted Date: 2017-03-27

Lead Sponsor: Biogen

Target Recruit Count: 646

Registration Number: NCT02219932

Locations: 🇷🇺
Research Site, Nizhny Novgorod, Russian Federation
🇬🇧
Research site, Nottingham, United Kingdom

A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults

Phase 1

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Study Drug
Drug: Active Control
Drug: Placebo

First Posted Date: 2014-07-28

Last Posted Date: 2019-11-26

Lead Sponsor: Biogen

Target Recruit Count: 104

Registration Number: NCT02201849

Locations: 🇺🇸
Alkermes Investigational Site, Austin, Texas, United States

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy

Phase 3

Terminated

Conditions: Spinal Muscular Atrophy

Interventions: Procedure: Sham procedure
Drug: nusinersen

First Posted Date: 2014-07-17

Last Posted Date: 2021-02-17

Lead Sponsor: Biogen

Target Recruit Count: 122

Registration Number: NCT02193074

Locations: 🇺🇸
Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
Children's Hospital of Philadelphia - Neurology, Philadelphia, Pennsylvania, United States
🇺🇸
UT Southwestern Medical Center/Children's Medical Center Dallas, Dallas, Texas, United States

and more 28 locations